<DOC>
	<DOCNO>NCT01098981</DOCNO>
	<brief_summary>This randomize , placebo-controlled , phase 3 clinical trial evaluate efficacy safety transcranial ultrasound ( US ) adjunctive therapy tissue plasminogen activator ( tPA ) treatment subject acute ischemic stroke .</brief_summary>
	<brief_title>Phase 3 , Randomized , Placebo-Controlled , Double-Blinded Trial Combined Lysis Thrombus With Ultrasound Systemic Tissue Plasminogen Activator ( tPA ) Emergent Revascularization Acute Ischemic Stroke</brief_title>
	<detailed_description>The primary objective trial provide information regard efficacy combine treatment transcranial US systemic tPA ( Target group ) compare systemic tPA alone ( Control group ) subject acute ischemic stroke . The primary efficacy endpoint functional outcome 3 month stroke onset ( modify Rankin Score ordinal shift analysis ) . The primary safety endpoint proportion subject Target v Control group experience symptomatic intracranial hemorrhage ( sICH ) within 24 hour treatment .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>Plasminogen</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<criteria>1 . Males females 18 80 year age 2 . Subjects present within timeframe intravenous tPA treatment approve local regulatory authority 4.5 hour onset symptom 3 . No sign intracranial bleed assessment noncontrast CT 4 . Subjects neurological deficit total NIHSS score ≥ 10 point 5 . Subjects opinion treat physician require treatment full dose IV tPA standard care per institutional standard 6 . SBP &lt; 185 mmHg DBP &lt; 105 mmHg baseline treatment hypertension medication prior tPA bolus 7 . Premorbid modify Rankin score 01 8 . Provision inform consent demonstrate subject 's signature signature subject 's authorized legal representative Informed Consent Form accordance local national regulation 9 . Cosignature Informed Consent Form qualify member study staff signifying , his/her professional opinion , informed consent obtain accordance local national regulation 10 . For subject optional arterial recanalization substudy : 1 . Occlusion locate intracranial carotid tee mid M2 proximal A2 , intracranial vertebrobasilar P1/proximal P2 segment tandem lesion 2 . Estimated glomerular filtration rate ( eGFR ) ≥ 60 mL/min patient undergo CTA MRA 1 . Subjects primary intraarterial thrombolysis 2 . Females pregnant breast feed 3 . Subjects receive investigational drug , procedure , therapy within 30 day prior study treatment 4 . Subjects standard contraindication intravenous tPA therapy 5 . Significant concurrent medical/neurological condition test value , opinion investigator , pose significant risk subject warrant exclusion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>